Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Vanguard Health Care Inv

Vanguard Total Stock Mkt Idx Inv

Fidelity 500 Index

iShares Core S&P 500 ETF

Canada Life US Small-Mid Cap Growth A

EARNEST Partners Smid Cap Core Founders

The Health Care Select Sector SPDR® ETF

iShares Biotechnology ETF

Vanguard Institutional Index I

M.D. Sass Concentrated Value

Van Berkom Sm-Cap Eq

Virtus KAR Small-Mid Cap Core R6

Allspring Special Mid Cap Value Inst

Allspring Special US Mid Cap Value Eq

Vanguard Institutional 500 Index Trust

Vanguard Small Cap Index

Vanguard Windsor Investor Shares

Vanguard Small Cap Growth Index Inv

Invesco S&P 500® Equal Weight ETF

SPDR® S&P 500® ETF Trust

Vanguard Group Inc

BlackRock Inc

Earnest Partners LLC

Bank of America Corp

Mackenzie Investments

Ariel Investments, LLC

Amvescap Plc.

Southpoint Capital Advisors LP

Franklin Resources Inc

SEI Investments Co

Wells Fargo & Co

Dimensional Fund Advisors, Inc.

Wellington Management Company LLP

State Street Corp

Kayne Anderson Rudnick Investment Management LLC

Allspring Global Investments Holdings, LLC

Geode Capital Management, LLC

Meritage Group LP

ClearBridge Advisors, LLC

Eminence Capital LLC

Charles River Laboratories

Mr. James C. Foster J.D.

CEO, President & Chairman

Ms. Flavia H. Pease

Corporate Executive VP & CFO

Ms. Birgit  Girshick

Corporate Executive VP & COO

Mr. Joseph W. LaPlume J.D.

Corporate Executive Vice President of Corporate Development & Strategy

Mr. William D. Barbo

Corporate Executive Vice President of Community Relations

Mr. Michael Gunnar Knell

Corporate Senior VP & Chief Accounting Officer

Prof. Julie  Frearson Ph.D.

Corporate Senior VP & Chief Scientific Officer

Mr. Mark  Mintz

Corporate Senior VP & Chief Information Officer

Mr. Todd  Spencer

Corporate Vice President of Investor Relations

Mr. Matthew L. Daniel J.D.

Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer

Charles River Laboratories (CRL) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Charles River Laboratories (CRL) Earnings Report Date and History | NYSE

CRL's next earnings is on February 12, 2025 (Before Market Open)

When is the earnings report for CRL?

CRL Earnings History

CRL Stock Discussion Forum and Message Board

News for NYSE: CRL